Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia

Blinatumoab公司 医学 内科学 肿瘤科 淋巴细胞白血病 化疗 白血病 儿科
作者
Franco Locatelli,Gerhard Zugmaier,Carmelo Rizzari,Joan Morris,Bernd Gruhn,Thomas Klingebiel,Rosanna Parasole,Christin Linderkamp,Christian Flotho,Arnaud Petit,Concetta Micalizzi,Noemi Mergen,Abeera Mohammad,William Kormany,Cornelia Eckert,Anja Möricke,Mary Sartor,Ondřej Hrušák,Christina Peters,Vaskar Saha
出处
期刊:JAMA [American Medical Association]
卷期号:325 (9): 843-843 被引量:255
标识
DOI:10.1001/jama.2021.0987
摘要

Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).To evaluate event-free survival in children with high-risk first-relapse B-ALL after a third consolidation course with blinatumomab vs consolidation chemotherapy before allogeneic hematopoietic stem cell transplant.In this randomized phase 3 clinical trial, patients were enrolled November 2015 to July 2019 (data cutoff, July 17, 2019). Investigators at 47 centers in 13 countries enrolled children older than 28 days and younger than 18 years with high-risk first-relapse B-ALL in morphologic complete remission (M1 marrow, <5% blasts) or with M2 marrow (blasts ≥5% and <25%) at randomization.Patients were randomized to receive 1 cycle of blinatumomab (n = 54; 15 μg/m2/d for 4 weeks, continuous intravenous infusion) or chemotherapy (n = 54) for the third consolidation.The primary end point was event-free survival (events: relapse, death, second malignancy, or failure to achieve complete remission). The key secondary efficacy end point was overall survival. Other secondary end points included minimal residual disease remission and incidence of adverse events.A total of 108 patients were randomized (median age, 5.0 years [interquartile range {IQR}, 4.0-10.5]; 51.9% girls; 97.2% M1 marrow) and all patients were included in the analysis. Enrollment was terminated early for benefit of blinatumomab in accordance with a prespecified stopping rule. After a median of 22.4 months of follow-up (IQR, 8.1-34.2), the incidence of events in the blinatumomab vs consolidation chemotherapy groups was 31% vs 57% (log-rank P < .001; hazard ratio [HR], 0.33 [95% CI, 0.18-0.61]). Deaths occurred in 8 patients (14.8%) in the blinatumomab group and 16 (29.6%) in the consolidation chemotherapy group. The overall survival HR was 0.43 (95% CI, 0.18-1.01). Minimal residual disease remission was observed in more patients in the blinatumomab vs consolidation chemotherapy group (90% [44/49] vs 54% [26/48]; difference, 35.6% [95% CI, 15.6%-52.5%]). No fatal adverse events were reported. In the blinatumomab vs consolidation chemotherapy group, the incidence of serious adverse events was 24.1% vs 43.1%, respectively, and the incidence of adverse events greater than or equal to grade 3 was 57.4% vs 82.4%. Adverse events leading to treatment discontinuation were reported in 2 patients in the blinatumomab group.Among children with high-risk first-relapse B-ALL, treatment with 1 cycle of blinatumomab compared with standard intensive multidrug chemotherapy before allogeneic hematopoietic stem cell transplant resulted in an improved event-free survival at a median of 22.4 months of follow-up.ClinicalTrials.gov Identifier: NCT02393859.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
5秒前
蓝意完成签到,获得积分0
6秒前
xiaohongmao完成签到,获得积分10
11秒前
14秒前
qweerrtt完成签到,获得积分10
21秒前
21秒前
与共发布了新的文献求助10
22秒前
carly完成签到 ,获得积分10
23秒前
颢懿完成签到 ,获得积分10
26秒前
量子星尘发布了新的文献求助10
27秒前
29秒前
ljc完成签到 ,获得积分10
30秒前
Java完成签到,获得积分10
34秒前
36秒前
鲤鱼安青完成签到 ,获得积分10
38秒前
38秒前
dollarpuff完成签到 ,获得积分10
41秒前
41秒前
mmmmmMM完成签到,获得积分10
48秒前
luckweb完成签到,获得积分10
54秒前
猫的毛完成签到 ,获得积分10
55秒前
nicky完成签到 ,获得积分10
56秒前
麦子完成签到 ,获得积分10
57秒前
57秒前
Wilson完成签到 ,获得积分10
58秒前
luckweb发布了新的文献求助10
58秒前
58秒前
1分钟前
1分钟前
传奇3应助wujiwuhui采纳,获得10
1分钟前
开心寄松完成签到,获得积分10
1分钟前
北宫完成签到 ,获得积分10
1分钟前
wansida完成签到,获得积分10
1分钟前
QXS完成签到 ,获得积分10
1分钟前
1分钟前
菠萝完成签到 ,获得积分10
1分钟前
领导范儿应助Villanellel采纳,获得10
1分钟前
wintersss完成签到,获得积分10
1分钟前
尹尹发布了新的文献求助10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022